X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aventis Pharma: Are valuations attractive? - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Feb 20, 2002

    Aventis Pharma: Are valuations attractive?

    Aventis Pharma (erstwhile Hoechst Marion) seems to be taking the right steps to inculcate much wanted growth in the company. While operating margins are on a steady rise, product portfolio of the company is increasingly becoming enviable. The company is slowly and steadily shifting its focus towards high margin specialised therapeutic segments. The DPCO order unfortunately seems to be acting as a dampener for the company's valuations.

    The operating margins of the company have been on an upward spiral thanks to the restructuring benefits and new product introductions. Aventis is slowly transforming from a company concentrated mainly on anti-infectives and pain management to a company specialising in life style therapeutic segments, where the margins are comparatively higher.

    The company is also expected to benefit from global bulk outsourcing by its parent company. The company’s Ankleshwar unit is already used by the parent company for this purpose as a sourcing base for a couple of bulk drugs (Ramipril and Articaine). It is expected that outsourcing by the parent company from HMR’s Goa plant would kick off shortly. This would be for Daonil (a leading product in anti-diabetic segment) from India for its European operations.

    However, going forward, we expect the company to show spikes in the margins based on product introductions. Further, though the company's product enjoys strong brand recall, it faces stiff competition from other domestic brands and generic products. For example, incase of Amaryl (anti-diabetic), there are already several generic competing products, which are priced below Amaryl. In a country like India where markets are absolutely price sensitive, premium pricing is difficult to continue. Thus, if the margins are to remain buoyant, product introductions will need to be strong. Going by the past experience the company has always benefited from fast product launches by its parent company.

    The effect of the proposed change in the DPCO is expected to be mixed. Some of its top selling drugs, covering around 10% of the total sales of the company are expected to go out of price control. However, Daonil, the company’s top selling anti-diabetic product is expected to come under DPCO coverage. Daonil contributes around 11% of the total sales of the company. Though the DPCO coverage of the company still remains high at around 35%, it is expected to drop sharply going forward inline with the change in the revenue structure.

    At the current market price of Rs 361, the stock trades at a P/E of 10.4x its FY02 earnings. The slide in the price of the stock seems to be on account of successive disappointments on non-relaxation of DPCO in favour of the company. However, considering the growth prospects and comparative valuations with the peers, the stock looks attractive at the current price.

    Comparative Valuations
    Particulars CMP P/E (x) P/E (x) Mkt. Cap Mkt.Cap/sales
      (Rs.) FY2002 FY2003 (Rs. Mn.) (x)
    Aventis Pharma 361 10.4 9.7 8,303 1.3
    GSK India 349 17.6 16.8 26,175 2.3
    Pfizer Ltd 462 23.1 20.1 10,626 2.6
    Novartis 255 13.9 11.8 8,135 1.7

     

     

    Equitymaster requests your view! Post a comment on "Aventis Pharma: Are valuations attractive?". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SANOFI INDIA SHARE PRICE


    Aug 21, 2017 (Close)

    TRACK SANOFI INDIA

    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SANOFI INDIA - ADCOCK INGRAM COMPARISON

    Compare Company With Charts

    COMPARE SANOFI INDIA WITH

    MARKET STATS